No Data
No Data
Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Foghorn Therapeutics Inc. (NASDAQ:FHTX) shares have had a horrible month, losing 25% after a relatively good period beforehand. Instead of being rewarded, shareholders who have already held through
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, a
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, and expected value was -0.63 dollars.
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
Foghorn Therapeutics | 10-Q: Quarterly report
Foghorn Therapeutics 1Q Loss $25M >FHTX
Foghorn Therapeutics 1Q Loss $25M >FHTX